Magnetic resonance imaging-guided versus computed tomography-guided stereotactic body radiotherapy for prostate cancer (MIRAGE): Interim analysis of a phase III randomized trial.
Amar U. Kishan(University of California, Los Angeles), Michael L. Steinberg(University of California, Los Angeles), Ting Martin(University of Washington), Ke Sheng(Wenzhou Medical University), Yingli Yang(University of California, Los Angeles), Daniel A. Low(University of California, Los Angeles), Xiaoyan Wang(Central South University), Yu Gao(University of California, Los Angeles), Maria Casado(University of California, Los Angeles), James Lamb(University of California, Los Angeles), Vincent Basehart(University of California, Los Angeles), Minsong Cao(Ronald Reagan UCLA Medical Center)
Cited by 30
Related Papers
Tolerance limits and methodologies for<scp>IMRT</scp>measurement‐based verification<scp>QA</scp>:<i>Recommendations of<scp>AAPM</scp>Task Group No. 218</i>
|Medical Physics|2018|1k
Adaptive Radiation Therapy (ART) Strategies and Technical Considerations: A State of the ART Review From NRG Oncology
|International Journal of Radiation Oncology*Biology*Physics|2020|314
External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline
|Practical Radiation Oncology|2021|261
A Multi-Institutional Experience of MR-Guided Liver Stereotactic Body Radiation Therapy
|Advances in Radiation Oncology|2018|161